Cash-Healthy Achillion Plans to Raise $125M Via Offering

With its hepatitis C virus (HCV) pipeline percolating and $77.4 million in the coffers as of the end of last year, Achillion Pharmaceuticals Inc. disclosed its plan to begin a public offering that would raise $125 million more, pursuant to a shelf registration.